Has Stephen Besh received payments from drug or device companies?

Yes. Drug and device makers reported $915 in general payments to Stephen Besh across 37 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Stephen Besh did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Stephen Besh come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Stephen Besh

Hematology & Oncology · Memphis, TNNPI 1659375392

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $738 of the $915 with a category attached, or 80.7%. It is spread thinly across 22 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $720, more than ten times the $12 reported in 2021. That places this record below the midpoint for hematology & oncology clinicians in TN, where the typical reported total is $5,575.

$915in general payments, 2019–2025

Across 37 payments — averaging $24.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Seagen Inc.$165
Pfizer$88
Novartis$87
Adaptive Biotechnologies Corporation$62
Gilead$60
AstraZeneca$42
plus $411 from 16 others

$37,298in research payments, 2019–2025

Across 6 payments — averaging $6216.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

AstraZeneca$27K
AbbVie$10K

What the payments were for

Food & beverage$73881%
Education$17719%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Seagen Inc.	2	$165
Pfizer	4	$88
Novartis	4	$87
Adaptive Biotechnologies Corporation	2	$62
Gilead	3	$60
AstraZeneca	2	$42
Merck	2	$41
E.r. Squibb & Sons, L.L.C.	2	$39
Puma Biotechnology, Inc.	2	$36
Servier Pharmaceuticals LLC	1	$30
Caris MPI, Inc.	2	$28
Beone Medicines USA, Inc.	1	$28
Daiichi Sankyo Inc.	1	$27
Bristol Myers Squibb	1	$26
Takeda Pharmaceuticals U.S.A., Inc.	1	$26
Lilly USA, LLC	1	$26
Eisai Inc.	1	$21
Stemline Therapeutics Inc.	1	$18
G1 Therapeutics, Inc.	1	$18
Taiho Oncology, Inc.	1	$16
Sobi, Inc	1	$16
Array Biopharma Inc	1	$14

How this compares

$915 in reported general payments places this provider in the 20th percentile of 251 hematology & oncology providers in Tennessee.

See all hematology & oncology providers in Tennessee →

Other hematology & oncology in Memphis

Ugochi OguMemphis$250K
Patricia Adams-GravesMemphis$168K
Donald GravenorMemphis$166K
Aleksandar JankovMemphis$163K
Brion RandolphMemphis$162K
Kenneth AtagaMemphis$157K
Raymond OsarogiagbonMemphis$117K
Saurin ChokshiMemphis$86K
Clyde JonesMemphis$54K
Salil GoorhaMemphis$51K

See the full list for Tennessee →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →